A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Sacituzumab Tirumotecan (Primary) ; Docetaxel
- Indications Carcinoma; Nasopharyngeal cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 28 Feb 2025 Planned End Date changed from 30 Oct 2025 to 30 Dec 2025.
- 28 Feb 2025 Planned primary completion date changed from 30 Oct 2024 to 30 Dec 2025.
- 28 Feb 2025 Status changed from recruiting to active, no longer recruiting.